QLS12010 in Moderate-to-Severe Hidradenitis Suppurativa

Phase 2, randomised, double-blind trial of QLS12010 in hidradenitis suppurativa (HS) (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Percent Change from Baseline in total abscess and inflammatory nodule count at 16 weeks and Incidence and severity of treatment emergent Adverse Events at 24 weeks. Planned start Apr 2026; status: not yet recruiting.